Patented advances in gyrocardiography bring affordable, clinical-grade disease detection to remote patients with smartphones.

CardioSignal and Mehiläinen, a well-known private provider of social and healthcare services in the Nordics, have formed a successful population health model to advance earlier detection of atrial fibrillation, a massive health care burden in the society today and a significant cause of hospitalization among older adults.

To break barriers in the scalability and accessibility of remote cardiac care technology among older adults, CardioSignal has become a portfolio company of AgeTech Collaborative™ from AARP® after completing its prestigious accelerator program.

Lasse Leppäkorpi, an entrepreneur, investor, and advisor with over 20 years of experience in health technology business development and biomedical engineering, has joined the CardioSignal team to boost the company’s international expansion.

CardioSignal Inc. announces US market entry with its novel technology for remote cardiac care, focusing on improving earlier detection of atrial fibrillation and heart failure with a smartphone.

As a first result of the collaboration, CardioSignal atrial fibrillation detection becomes available in OMRON connect app Premium Service in selected countries in Europe.